Pfizer PFE will report its second-quarter 2025 earnings on Aug. 5, before market open. The Zacks Consensus Estimate for sales ...

Pregnant individuals commonly reported hesitancy toward RSVpreF and nirsevimab, indicating the need for efforts to promote the safety and uptake of RSV immunization.

Parental trust in clinicians drove RSV vaccine uptake, while confusion and limited access to reliable information hindered ...

Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

In older adults, respiratory syncytial virus (RSV) is associated with an increased risk for cardiovascular outcome, especially heart failure events.

The Clinical Advisor spoke with Audrey M. Stevenson, PhD, MPH, MSN, FNP-BC, about how the changes to ACIP will affect vaccination recommendations moving forward. Dr Stevenson is a faculty member of ...

Children hospitalized with RSV showed higher risk for ICU admission, IMV, and supplemental oxygen than children hospitalized with COVID-19 or influenza.

Experts urge people to get vaccinated against the flu, after the death of a little girl from the virus in Perth.

Here's Why Kennedy Says the Mumps Vaccine Doesn't Work — Expert suggests it has something to do with his work as a personal injury lawyer ...

Sanofi SNY reported second-quarter 2025 adjusted earnings of 90 cents per American depositary share, which missed the Zacks ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into ...